triciribine has been researched along with Benign Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, C; Lee, H; Solomon, VR; Ulibarri, G | 1 |
| Cohen, PA; Donini, CF; Lincet, H; Nguyen, NT; Vendrell, JA | 1 |
| Cseh, A; Szalay, B; Szebeni, B; Vásárhelyi, B | 1 |
| Esteva, FJ; Hortobagyi, GN; Lan, KH; Lu, CH; Mills, GB; Neal, CL; Sun, MH; Tseng, LM; Wyszomierski, SL; Yu, D | 1 |
1 review(s) available for triciribine and Benign Neoplasms
| Article | Year |
|---|---|
The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Differentiation; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasms; Neoplastic Stem Cells; Prognosis; Ribonucleosides; Signal Transduction; Trans-Activators | 2015 |
3 other study(ies) available for triciribine and Benign Neoplasms
| Article | Year |
|---|---|
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Chloroquine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Stereoisomerism; Structure-Activity Relationship | 2008 |
[Akt enzyme: new therapeutic target in cancer and diabetes?].
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Diabetes Mellitus; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin Resistance; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Ribonucleosides | 2009 |
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Everolimus; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms; PTEN Phosphohydrolase; Ribonucleosides; Sirolimus; Trastuzumab | 2007 |